SHOC2 mRNA is abundant in adult testis and immune tissues as well as in fetal brain. The c.4A>G (p.S2G) mutation was not detected in 82 samples from patients with leukemia.

Clinical manifestations in *SHOC2* mutation-positive patients often vary, even among patients who have a common p.S2G mutation (Table 2 and Supplementary Table 4). In this study and in a previous study, relative macrocephaly (94%), hypertelorism (79%), low-set ears (91%) and short stature (100%) were frequently observed in patients with the *SHOC2* p.S2G mutation.[18] Growth hormone deficiency was observed in 70% of patients. With respect to cardiac abnormalities, pulmonic stenosis was observed in 13 of 33 patients (39%), followed by atrial septal defect (33%), mitral valve anomaly (31%) and hypertrophic cardiomyopathy (27%). Dark skin and atopic dermatitis were seen in 75 and 48% of patients, respectively. Hair abnormalities, including sparse hair (100%) and loose anagen hair/easily pluckable hair (100%), were the most characteristic clinical features of *SHOC2* mutation-positive patients.

The symptomatology of patients with the *SHOC2* mutation does not fit existing disorders, including Noonan, Costello and CFC syndrome. In this paper, we summarize the clinical manifestations of patients with CFC syndrome[21,22] or Noonan syndrome,[23] as described in previous reports, as well as *SHOC2* mutation-positive patients (Table 2). The high frequencies of mental retardation (84%) and sparse hair (100%) observed in *SHOC2* mutation-positive patients are similar to those observed in CFC patients (100 and 89%, respectively); the frequency of mental retardation was higher than that in patients with Noonan syndrome (42%). With respect to cardiac abnormalities, the frequencies of hypertrophic cardiomyopathy, atrial septal defect and mitral valve anomaly are similar to those among patients with Noonan syndrome. However, pulmonic stenosis (39%) was less frequent in *SHOC2* mutation-positive patients than in patients with Noonan syndrome (63%). It is of note that short stature (100%) and pectus deformity (72%) were found to be most frequent in patients with the *SHOC2* mutation. Furthermore, loose anagen/easily pluckable hair has not been reported in mutation-positive patients with Noonan, CFC or Costello syndrome. Taken together, these results suggest that clinical manifestations in patients with *SHOC2* partially overlap with those of Noonan syndrome and CFC syndrome. The presence of easily pluckable/loose anagen hair is distinctive in *SHOC2* mutation-positive patients.

Loose anagen hair has been observed in an isolated loose anagen hair syndrome (OMIM 600628)[24] and has been found to be associated with Noonan syndrome.[25,26] The pathogenesis of loose anagen hair remains unknown. A scalp biopsy in a patient with loose anagen hair showed marked cleft formation between the inner root and the irregularly shaped hair shafts. Abnormalities in the keratin gene have been suggested.[24] Functional analysis of the *SHOC2* p.S2G mutant showed that the mutant protein was aberrantly localized in the membrane fraction after stimulation with epidermal growth factor and induced extracellular signal-regulated kinase signaling in a cell-specific manner.[18] It is possible that dysregulated proliferation or cell-to-cell attachment causes the detachment between inner sheaths and hair shafts.

One of our mutation-positive patients exhibited a remarkable leukocytosis ranging from 12 000 to 24 600/mm^3. Other patients also showed mild leukocytosis, which is near the upper range of the normal levels for their age. This observation led us to examine the tissue and cellular expression of *SHOC2*. In adult tissues, the highest *SHOC2* expression was observed in testis; relatively high expression was also observed in several immune tissues, including spleen, bone marrow, tonsil and lymph node. Among leukocytes, the expression of *SHOC2* was six times higher in PMN than in mononuclear, suggesting that *SHOC2* might be important to the proliferation or survival of PMN leukocytes. We did not identify the p.S2G mutation in 82 samples from patients with hematologic malignancies. A recent study reported that no *SHOC2* mutations were identified in 22 patients with juvenile myelomonocytic leukemia.[27] It is possible that the absence of mutation was due to the relatively small sample size. Alternatively, the gain of function of *SHOC2* might not have leukemogenic potential, and other factors such as aberrant cytokine production may be associated with leukocytosis.

In summary, we identified the *SHOC2* p.S2G mutation in eight patients with Noonan-like syndrome. Analysis of the detailed clinical manifestations of these patients showed that relative macrocephaly, hypertelorism, low-set ears, short stature, sparse/easily pluckable hair and a variety of skin abnormalities, including dark skin and atopic dermatitis, are frequently observed in patients positive for this mutation. A previous study and this study show that only one mutation (p.S2G) is causative for the phenotype. The rapid detection system for the *SHOC2* p.S2G mutation using the Lightcycler will be a useful tool to screen for this mutation in patient samples.

ACKNOWLEDGEMENTS

We thank the patients and families who participated in this study as well as the doctors who referred the patients. This work was supported by Grants-in-Aids from the Ministry of Education, Culture, Sports, Science and Technology of Japan, Japan Society for the Promotion of Science and The Ministry of Health Labour and Welfare to YM and YA.

1 Allanson, J. E., Hall, J. G., Hughes, H. E., Preus, M. & Witt, R. D. Noonan syndrome: the changing phenotype. *Am. J. Med. Genet.* **21,** 507–514 (1985).
2 van der Burgt, I. Noonan syndrome. *Orphanet. J. Rare Dis.* **2,** 4 (2007).
3 Hennekam, R. C. Costello syndrome: an overview. *Am. J. Med. Genet. C Semin. Med. Genet.* **117,** 42–48 (2003).
4 Reynolds, J. F., Neri, G., Herrmann, J. P., Blumberg, B., Coldwell, J. G., Miles, P. V. *et al.* New multiple congenital anomalies/mental retardation syndrome with cardio-facio-cutaneous involvement–the CFC syndrome. *Am. J. Med. Genet.* **25,** 413–427 (1986).
5 Aoki, Y., Niihori, T., Narumi, Y., Kure, S. & Matsubara, Y. The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders. *Hum. Mutat.* **29,** 992–1006 (2008).
6 Bentires-Alj, M., Kontaridis, M. I. & Neel, B. G. Stops along the RAS pathway in human genetic disease. *Nat. Med.* **12,** 283–285 (2006).
7 Pandit, B., Sarkozy, A., Pennacchio, L. A., Carta, C., Oishi, K., Martinelli, S. *et al.* Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. *Nat. Genet.* **39,** 1007–1012 (2007).
8 Razzaque, M. A., Nishizawa, T., Komoike, Y., Yagi, H., Furutani, M., Amo, R. *et al.* Germline gain-of-function mutations in RAF1 cause Noonan syndrome. *Nat. Genet.* **39,** 1013–1017 (2007).
9 Roberts, A. E., Araki, T., Swanson, K. D., Montgomery, K. T., Schiripo, T. A., Joshi, V. A. *et al.* Germline gain-of-function mutations in SOS1 cause Noonan syndrome. *Nat. Genet.* **39,** 70–74 (2007).
10 Schubbert, S., Zenker, M., Rowe, S. L., Boll, S., Klein, C., Bollag, G. *et al.* Germline KRAS mutations cause Noonan syndrome. *Nat. Genet.* **38,** 331–336 (2006).
11 Tartaglia, M., Mehler, E. L., Goldberg, R., Zampino, G., Brunner, H. G., Kremer, H. *et al.* Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. *Nat. Genet.* **29,** 465–468 (2001).
12 Tartaglia, M., Pennacchio, L. A., Zhao, C., Yadav, K. K., Fodale, V., Sarkozy, A. *et al.* Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome. *Nat. Genet.* **39,** 75–79 (2007).
13 Aoki, Y., Niihori, T., Kawame, H., Kurosawa, K., Ohashi, H., Tanaka, Y. *et al.* Germline mutations in HRAS proto-oncogene cause Costello syndrome. *Nat. Genet.* **37,** 1038–1040 (2005).
14 Niihori, T., Aoki, Y., Narumi, Y., Neri, G., Cave, H., Verloes, A. *et al.* Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome. *Nat. Genet.* **38,** 294–296 (2006).
15 Rodriguez-Viciana, P., Tetsu, O., Tidyman, W. E., Estep, A. L., Conger, B. A., Cruz, M. S. *et al.* Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome. *Science.* **311,** 1287–1290 (2006).

16 Selfors, L. M., Schutzman, J. L., Borland, C. Z. & Stern, M. J. soc-2 encodes a leucine-rich repeat protein implicated in fibroblast growth factor receptor signaling. *Proc. Natl Acad. Sci. USA* **95,** 6903–6908 (1998).
17 Rodriguez-Viciana, P., Oses-Prieto, J., Burlingame, A., Fried, M. & McCormick, F. A phosphatase holoenzyme comprised of Shoc2/Sur8 and the catalytic subunit of PP1 functions as an M-Ras effector to modulate Raf activity. *Mol. Cell.* **22,** 217–230 (2006).
18 Cordeddu, V., Di Schiavi, E., Pennacchio, L. A., Ma'ayan, A., Sarkozy, A., Fodale, V. *et al.* Mutation of SHOC2 promotes aberrant protein N-myristoylation and causes Noonan-like syndrome with loose anagen hair. *Nat. Genet.* **41,** 1022–1026 (2009).
19 Makita, Y., Narumi, Y., Yoshida, M., Niihori, T., Kure, S., Fujieda, K. *et al.* Leukemia in cardio-facio-cutaneous (CFC) syndrome: a patient with a germline mutation in BRAF proto-oncogene. *J. Pediatr. Hematol. Oncol.* **29,** 287–290 (2007).
20 Ohtake, A., Aoki, Y., Saito, Y., Niihori, T., Shibuya, A., Kure, S. *et al.* Non-Hodgkin lymphoma in a patient with cardio-facio-cutaneous syndrome. *J. Pediatr. Hematol. Oncol.* (e-pub ahead of print 2 June 2010).
21 Armour, C. M. & Allanson, J. E. Further delineation of cardio-facio-cutaneous syndrome: clinical features of 38 individuals with proven mutations. *J. Med. Genet.* **45,** 249–254 (2008).
22 Narumi, Y., Aoki, Y., Niihori, T., Neri, G., Cave, H., Verloes, A. *et al.* Molecular and clinical characterization of cardio-facio-cutaneous (CFC) syndrome: overlapping clinical manifestations with Costello syndrome. *Am. J. Med. Genet. A.* **143A,** 799–807 (2007).
23 Kobayashi, T., Aoki, Y., Niihori, T., Cave, H., Verloes, A., Okamoto, N. *et al.* Molecular and clinical analysis of RAF1 in Noonan syndrome and related disorders: dephosphorylation of serine 259 as the essential mechanism for mutant activation. *Hum. Mutat.* **31,** 284–294 (2010).
24 Tosti, A. & Piraccini, B. M. Loose anagen hair syndrome and loose anagen hair. *Arch. Dermatol.* **138,** 521–522 (2002).
25 Mazzanti, L., Cacciari, E., Cicognani, A., Bergamaschi, R., Scarano, E. & Forabosco, A. Noonan-like syndrome with loose anagen hair: a new syndrome? *Am. J. Med. Genet. A.* **118A,** 279–286 (2003).
26 Tosti, A., Misciali, C., Borrello, P., Fanti, P. A., Bardazzi, F. & Patrizi, A. Loose anagen hair in a child with Noonan's syndrome. *Dermatologica.* **182,** 247–249 (1991).
27 Flotho, C., Batz, C., Hasle, H., Bergstrasser, E., van den Heuvel-Eibrink, M. M., Zecca, M. *et al.* Mutational analysis of SHOC2, a novel gene for Noonan-like syndrome, in JMML. *Blood.* **115,** 913 (2010).

Supplementary Information accompanies the paper on Journal of Human Genetics website (http://www.nature.com/jhg)

RESEARCH ARTICLE

Human Mutation

OFFICIAL JOURNAL
HGVS
HUMAN GENOME VARIATION SOCIETY
www.hgvs.org

Molecular and Clinical Analysis of *RAF1* in Noonan Syndrome and Related Disorders: Dephosphorylation of Serine 259 as the Essential Mechanism for Mutant Activation

Tomoko Kobayashi,[1] Yoko Aoki,[1]* Tetsuya Niihori,[1] Hélène Cavé,[2] Alain Verloes,[2] Nobuhiko Okamoto,[3] Hiroshi Kawame,[4,5] Ikuma Fujiwara,[6] Fumio Takada,[7] Takako Ohata,[7] Satoru Sakazume,[8] Tatsuya Ando,[9] Noriko Nakagawa,[10] Pablo Lapunzina,[11] Antonio G. Meneses,[11] Gabriele Gillessen-Kaesbach,[12] Dagmar Wieczorek,[13] Kenji Kurosawa,[14] Seiji Mizuno,[15] Hirofumi Ohashi,[16] Albert David,[17] Nicole Philip,[18] Afag Guliyeva,[1] Yoko Narumi,[1] Shigeo Kure,[1,6] Shigeru Tsuchiya,[6] and Yoichi Matsubara[1]

[1]Department of Medical Genetics, Tohoku University School of Medicine, Sendai, Japan; [2]APHP, Hôpital Robert Debré, Département de Génétique; Université Paris 7-Denis Diderot, Paris, France; [3]Department of Medical Genetics, Osaka Medical Center and Research Institute for Maternal and Child Health, Izumi, Osaka, Japan; [4]Division of Medical Genetics, Nagano Children's Hospital, Nagano, Japan; [5]Department of Genetic Counseling, Ochanomizu University, Tokyo, Japan; [6]Department of Pediatrics, Tohoku University School of Medicine, Sendai, Japan; [7]Department of Medical Genetics, Kitasato University Graduate School of Medical Sciences, Sagamihara, Japan; [8]Division of Medical Genetics, Gunma Children's Medical Center, Gunma, Japan; [9]Department of Pediatrics, Jikei University School of Medicine, Tokyo, Japan; [10]Department of Pediatrics, National Defense Medical College, Tokorozawa, Saitama, Japan; [11]Servicio de Genetica Medica, Hospital Universitario La Paz, Madrid, Spain; [12]Institut für Humangenetik Lübeck, Universitätsklinikum Schleswig-Holstein, Lübeck, Germany; [13]Institut für Humangenetik, Universitaetsklinikum Essen Universitaet Duisburg-Essen, Essen, Germany; [14]Division of Medical Genetics, Kanagawa Children's Medical Center, Yokohama, Japan; [15]Department of Pediatrics, Central Hospital, Aichi Human Service Center, Aichi, Japan; [16]Division of Medical Genetics, Saitama Children's Medical Center, Saitama, Japan; [17]CHU Nantes, Nantes, France; [18]Hôpital de la Timone, Marseille, France

Communicated by Nancy B. Spinner

Received 20 July 2009; accepted revised manuscript 2 December 2009.
Published online 5 January 2010 in Wiley InterScience (www.interscience.wiley.com). DOI 10.1002/humu.21187

ABSTRACT: Noonan syndrome (NS) and related disorders are autosomal dominant disorders characterized by heart defects, facial dysmorphism, ectodermal abnormalities, and mental retardation. The dysregulation of the RAS/MAPK pathway appears to be a common molecular pathogenesis of these disorders: mutations in *PTPN11*, *KRAS*, and *SOS1* have been identified in patients with NS, those in *KRAS*, *BRAF*, *MAP2K1*, and *MAP2K2* in patients with CFC syndrome, and those in *HRAS* mutations in Costello syndrome patients. Recently, mutations in *RAF1* have been also identified in patients with NS and two patients with LEOPARD (multiple lentigines, electrocardiographic conduction abnormalities, ocular hypertelorism, pulmonary stenosis, abnormal genitalia, retardation of growth, and sensorineural deafness) syndrome. In the current study, we identified eight *RAF1* mutations in 18 of 119 patients with NS and related conditions without mutations in known genes. We summarized clinical manifestations in patients with *RAF1* mutations as well as those in NS patients with *PTPN11*, *SOS1*, or *KRAS* mutations previously reported. Hypertrophic cardiomyopathy and short stature were found to be more frequently observed in patients with *RAF1* mutations. Mutations in *RAF1* were clustered in the conserved region 2 (CR2) domain, which carries an inhibitory phosphorylation site (serine at position 259; S259). Functional studies revealed that the RAF1 mutants located in the CR2 domain resulted in the decreased phosphorylation of S259, and that mutant RAF1 then dissociated from 14-3-3, leading to a partial ERK activation. Our results suggest that the dephosphorylation of S259 is the primary pathogenic mechanism in the activation of RAF1 mutants located in the CR2 domain as well as of downstream ERK.
Hum Mutat 31:284–294, 2010. © 2010 Wiley-Liss, Inc.

KEY WORDS: RAS; MAPK; RAF1; Noonan syndrome; PTPN11; hypertrophic cardiomyopathy

Introduction

Noonan syndrome (NS; MIM# 163950) is an autosomal dominant developmental disorder characterized by facial dysmorphism, including hypertelorism, low-set ears, ptosis, short stature, skeletal abnormalities, and heart defects [Allanson et al., 1985; Mendez and Opitz, 1985]. Frequently observed features in NS patients are pulmonary stenosis (PS), hypertrophic cardiomyopathy, chest deformities, a webbed/short neck, mental

Additional Supporting Information may be found in the online version of this article.

Present address of Yoko Narumi: Department of Medical Genetics, Shinshu University School of Medicine, Matsumoto, Japan.

*Correspondence to: Yoko Aoki, Department of Medical Genetics, Tohoku University School of Medicine, 1-1 Seiryo-machi, Sendai 980-8574, Japan.
E-mail: aokiy@mail.tains.tohoku.ac.jp

retardation, genitourinary defects including cryptorchidism in males, and bleeding diathesis due to factor XI deficiency. The incidence of this syndrome is estimated to be 1 in 1,000–2,500 live births. LEOPARD (multiple *l*entigines, *e*lectrocardiographic conduction abnormalities, *o*cular hypertelorism, *p*ulmonary stenosis, *a*bnormal genitalia, *r*etardation of growth, and sensorineural *d*eafness) syndrome (MIM# 151100) is known to be a NS-related disorder [Digilio et al., 2002]. The features of NS overlap with those of Costello syndrome and cardio-facio-cutaneous (CFC) syndrome. Patients with Costello syndrome (MIM# 218040) show distinctive facial features, mental retardation, high birth weight, neonatal feeding problems, curly hair, nasal papillomata, deep skin creases at palms and soles, and hypertrophic cardiomyopathy [Hennekam, 2003]. CFC syndrome (MIM# 115150) is characterized by distinctive facial features, mental retardation, heart defects (PS, atrial septal defect [ASD], and hypertrophic cardiomyopathy), and ectodermal abnormalities such as sparse, friable hair, hyperkeratotic skin lesions, and a generalized ichthyosis-like condition [Reynolds et al., 1986].

The molecular pathogenesis of these syndromes has been investigated. Tartaglia et al. [2001] have identified missense mutations in *PTPN11*, a gene encoding protein tyrosine phosphatase (PTP) SHP-2, in 45% of clinically diagnosed NS patients. Specific mutations in *PTPN11* has been identified in patients with LEOPARD syndrome [Digilio et al., 2002]. In 2005, we identified *HRAS* germline mutations in patients with Costello syndrome [Aoki et al., 2005]. Mutations in *KRAS*, *BRAF*, and *MAP2K1/2* have been identified in those with CFC syndrome [Niihori et al., 2006; Rodriguez-Viciana et al., 2006]. Mutations in *KRAS* and *SOS1* have also been identified in patients with NS [Roberts et al., 2007; Schubbert et al., 2006; Tartaglia et al., 2007]. Mutations in *NF1* and *SPRED1* have been identified in patients with neurofibromatosis type I (MIM# 162200) [Brems et al., 2007]. These findings suggest that dysregulation of the RAS/RAF/MEK/ERK pathway causes NS and related disorders, and thus it has been suggested that these syndromes be comprehensively termed the RAS/MAPK syndromes [Aoki et al., 2008] or the neuro-cardio-facial-cutaneous syndrome [Bentires-Alj et al., 2006].

In 2007, gain-of-function mutations in *RAF1* were identified in 3–17% of patients with NS and two patients with LEOPARD syndrome [Pandit et al., 2007; Razzaque et al., 2007]. RAF1 is a member of the RAF serine–threonine kinase family and transmits the upstream RAS signaling to downstream MEK and ERK. RAF1, ARAF, and BRAF share three conserved regions, CR1, CR2, and CR3 [Mercer and Pritchard, 2003]. Mutations in *BRAF* identified in patients with CFC syndrome are clustered in CR1 and CR3 domains [Aoki et al., 2008]. In contrast, reported *RAF1* mutations in NS and LEOPARD syndrome were located in the CR2 domain and some mutations were located in CR3 domain. These mutants had enhanced RAF1 kinase activities and most mutations, but not all, showed enhanced phosphorylation of ERK1/2 [Pandit et al., 2007; Razzaque et al., 2007]. Pandit et al. [2007] suggested that RAF1 mutations might interfere with RAF1 phosphorylation at serine 259 as well as with 14-3-3 interaction, and reported that p.P261S did not bind to 14-3-3. However, the mechanisms of RAF1 activation in mutants remain unexplained.

In the present study, we analyzed the *RAF1* gene in 119 patients with NS and related phenotypes without mutations in *PTPN11*, *HRAS*, *KRAS*, *BRAF*, *MAP2K1/2*, and *SOS1*. Detailed clinical manifestations in our new patients with *RAF1* mutations were evaluated, and those in patients with *RAF1 KRAS*, *PTPN11*, and *SOS1* mutations previously reported by us and others were examined. Furthermore, we explored the molecular mechanisms by which RAF1 mutants are activated.

Materials and Methods

Patients

One hundred nineteen patients with NS or related phenotypes were recruited. The primary diagnoses made by clinical dysmorphologists and general pediatricians were as follows: 44 patients with NS, 46 patients with CFC syndrome, 25 patients with Costello syndrome, and 4 patients with atypical phenotypes. No mutations in *PTPN11*, *HRAS*, *KRAS*, *BRAF*, *MAP2K1*, *MAP2K2*, or *SOS1* were identified in these patients. Control DNA was obtained from 105 healthy Japanese individuals. Control DNA from 105 healthy Caucasian individuals was purchased from Coriell Cell Repositories (Camden, NJ). This study was approved by the Ethics Committee of Tohoku University School of Medicine. We obtained informed consent from all subjects involved in the study and specific consent for photographs from six patients.

Mutation Analysis in *RAF1*

Genomic DNA was isolated from the peripheral blood leukocytes of the patients. Each exon with flanking intronic sequences in *RAF1* was amplified with primers based on GenBank sequences (Supp. Table S1; GenBank accession no. NC_000003.10). The M13 reverse or forward sequence was added to the 5′ end of the polymerase chain reaction (PCR) primers for use as a sequencing primer. PCR was performed in 30 μl of a solution containing 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM $MgCl_2$, 0.2 mM dNTP, 10% (v/v) DMSO, 24 pmol of each primer, 100 ng genomic DNA, and 1.5 units of Taq DNA polymerase. The reaction conditions consisted of 35 cycles of denaturation at 94°C for 15 sec, annealing at 55°C for 15 sec, and extension at 72°C for 40 sec. The products were gel-purified and sequenced on an ABI PRISM 310 or 3130 automated DNA sequencer (Applied Biosystems, Foster City, CA).

Determination of the RAF1 Phosphorylation Status

The expression construct, including a *RAF1* cDNA (pUSEamp-*RAF1*), was purchased from Millipore (Billerica, MA). A Myc-tag was introduced at the 5′ terminus of the cDNA by PCR and the PCR product was subcloned into pCR4-TOPO (Invitrogen, Carlsbad, CA). The entire cDNA was verified by sequencing. A single-base substitution resulting in p.H103Q, p.R191I, p.S257L, p.S259F, p.P261A, p.N262K, or p.S427G was introduced using a QuickChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA). All mutant constructs were verified by sequencing. The Myc-tagged wild-type *RAF1* cDNA and mutant cDNAs were digested with *Eco*RI and *Eco*RV and subcloned into the *Eco*RI–*Eco*RV site of the pUSEamp-*RAF1*.

COS7 cells were purchased from the American Type Culture Collection (ATCC, Rockville, MD). Cells were maintained in DMEM containing 10% fetal calf serum (FCS), 50 U/ml penicillin, and 50 μg/ml streptomycin. COS7 cells were seeded at 1×10^5 cells per 6-cm dish, and 24 hr later, 2.0 μg of pUSE vectors encoding one of the wild-type (WT) or mutant RAF1 cDNAs were transfected using 8 μl of PLUS Reagent and 12 μl of Lipofectamine Reagent (Invitrogen). After 3 hr, the medium was replaced to complete medium. After 48-hr culture, cells were scraped and collected by centrifugation after two washes with phosphate-buffered saline

(PBS). Lysates were prepared in 100-μl lysis buffer (10 mM Tris-HCl pH 8.0 and 1% SDS) and boiled for 3 min. The DNA was sheared with a syringe. The lysates were centrifuged at 14,000 × *g* for 15 min at 4°C and protein concentration was determined by Bradford assay. Thirty micrograms of protein was subjected to SDS-polyacrylamide gel electrophoresis (5–20% gradient gel) (ATTO, Tokyo, Japan), transferred to nitrocellulose membrane, and probed with anti-Myc antibody and phospho-specific RAF1 antibodies (Cell Signaling, Danvers, MA). All the membranes were visualized using a Western Lightning ECL-Plus Kit (Perkin-Elmer, Norwalk, CT). The following antibodies were used for Western blotting: anti-Myc (9E10, Santa Cruz Biotech, Santa Cruz, CA), antiphospho-c-Raf (S259) (Cell Signaling), antiphospho-c-Raf (S338) (Millipore), antiphospho-c-Raf (S289/296/301) (Cell Signaling), antiphospho-c-Raf (S621) (Millipore), and antineomycin phosphotransferase II (Millipore).

For immunoprecipitation, lysates were prepared in 1 ml of ice-cold RIPA buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM EDTA, 1:100 protease inhibitor (Sigma, St. Louis, MO), 1:1000 phosphatase inhibitor (Sigma), and 1% Triton X) and incubated on ice for 15 min. Four hundred micrograms of protein was incubated with anti-Myc (9E10) antibody for 1 hr at 4°C. Immune complexes were collected by adding 50 μl of 50% protein G-Sepharose bead slurry (GE Healthcare, Milwaukee, WI) for 1 hr at 4°C, washed three times with RIPA buffer, and then boiled in 2 × SDS buffer. The samples were resolved in 5–20% gradient polyacrylamide gels, transferred to nitrocellulose membranes and probed with antiphospho-c-Raf (S259) and anti-Myc (9E10) antibodies.

Reporter Assay

NIH 3T3 cells (ATCC) were maintained in DMEM containing 10% newborn calf serum, 50 U/ml penicillin, and 50 μg/ml of streptomycin. One day prior to the transfection, the NIH 3T3 cells were plated in 12-well plates with a density of 1×10^5 cells per well. Cells were transiently transfected using Lipofectamine and PLUS Reagents with 700 ng of pFR-luc, 15 ng of pFA2-Elk1, 7 ng of phRLnull-luc, and 35 ng of WT or mutant expression constructs of *RAF1*. Eighteen hours after transfection, the cells were cultured in DMEM without serum for 24 hr. Cells were harvested in passive lysis buffer, and luciferase activity was assayed using a Dual-Luciferase Reporter Assay System (Promega, Madison, WI). Renilla luciferase expressed by phRLnull-luc was used to normalize the transfection efficiency. The experiments were performed in triplicate. Data are shown as mean ± SD. Statistical analysis was performed using Excel.

Binding of RAF1 with 14-3-3

An expression construct containing Myc- and Flag-tagged 14-3-3 ζ (pCMV6-14-3-3 ζ) was purchased from Origene (Rockville, MD). In order to remove the Myc-tag from the construct, the 3′ half of the cDNA and the Myc-tag were removed by digestion with *Eco*RV and the 3′ half of cDNA was filled using PCR. An S621A mutation, which impairs phosphorylation of S621 to bind 14-3-3, was introduced into pUSE RAF1 harboring WT, p.S257L, or p.N262K cDNA by a Quickchange Site-Directed Mutagenesis Kit. HEK293 cells (ATCC) were transfected with 2 μg RAF1 constructs and 2 μg pCMV6-14-3-3 ζ construct using Lipofectamine and PLUS Reagents. After 48 hr, cells were scraped and collected by centrifugation after two washes with PBS. Lysates were prepared as described above. The Myc-tagged RAF1 was immunoprecipitated with anti-Myc antibody (clone4A6, Millipore) for 1 hr at 4°C. Immune complexes were collected by adding 50 μl of 50% protein G-Sepharose bead slurry (GE Healthcare) for 1 hr at 4°C, washed three times with RIPA buffer, and then boiled in 2 × SDS buffer. The samples were resolved in 5–20% gradient polyacrylamide gels, transferred to nitrocellulose membranes, and probed with anti-FLAG M2 (Sigma) and anti-Myc antibodies. For immunoprecipitation of 14-3-3, anti-FLAG M2 antibody was used and immunoblotting was performed using anti-FLAG M2 and anti-c-Raf (Cell Signaling) antibodies.

Results

Mutation Analysis in Patients

We identified eight amino acid changes in 18 patients (Table 1). A C-to-T nucleotide change, resulting in an amino acid change p.S257L, was identified in 11 patients. Novel p.R191I (c.572G>T) and p.N262K (c.786T>A) were identified in one each patient. Previously reported mutations, including p.S259F (c.776C>T), p.P261A (c.781C>G), p.P261L (c.782C>T), p.S427G (c.1279A>G), and p.L613V (c.1837C>G), were identified in a single patient. Nucleotide numbering reflects cDNA numbering with +1 corresponding to the A of the ATG translation initiation codon in Genbank NM_002880.3, according to journal guidelines (www.hgvs.org/mutnomen). The initiation codon is codon 1. The mutation p.S427G, which has been reported in a patient with therapy-related acute myeloid leukemia [Zebisch et al., 2006], was identified in one patient. None of the newly identified mutations were observed in the control DNA of 105 ethnically matched healthy subjects. Parental samples were obtained from six patients (NS86, 92, 209, 210, 222, and 258). The analysis showed that p.S257L, p.P261A, and p.N262K occurred de novo. p.S427G was also identified as well in his 32-year-old mother, who also exhibited a Noonan phenotype with distinctive facial appearance, sparse hair in infancy, and multiple lentigines. The p.H103Q (c.309C>G) was identified in patient NS86, in whom p.S257L was also identified. This amino acid change was identified in one of his parents without any clinical features, suggesting that this amino acid change was polymorphic.

Clinical Manifestations of Patients with *RAF1* Mutations

Initial diagnoses of patients with *RAF1* mutations were as follows: NS in 11 patients, CFC syndrome in 4 patients, and Costello in 3 patients (Supp. Table S2). Four patients who were first diagnosed as having CFC syndrome were reclassified as NS because of facial features and normal mental development after identification of *RAF1* mutations. Three patients were diagnosed as having Costello syndrome. One patient was rediagnosed as having NS (NS135) and the other patient died at 1 month (NS209). Detailed information on clinical manifestations of NS205 was not available.

Detailed clinical manifestations in 18 patients with *RAF1* mutations were evaluated (Table 2 and Fig. 1). Nine of 15 patients had prenatal abnormality, including cystic hygroma, polyhydramnions, and asphyxia. Most patients had characteristic craniofacial abnormalities frequently observed in NS: relative macrocephaly (94%), hypertelorism (93%), downslanting palpebral fissures (63%), epicanthal folds (86%), and low-set ears (93%). Mental retardation was observed in 6 of 11 (55%) patients. Short stature (73%), short neck (93%), and webbing of neck (81%) were also observed. As for cardiac abnormalities, hypertrophic cardiomyopathy was observed in 10 of 16 patients (63%), followed by pulmonic stenosis (47%),

Table 1. *RAF1* Mutations Identified in This Study*

Patient ID	Country of origin	Final diagnosis	Exon	Nucleotide change	Amino acid change	Domain	Genotype of father/mother
NS213	France	atypical NS	5	c. 572G>T	p.R191I[a]	CR1	NA
NS39	Japan	NS	7	c.770C>T	p.S257L	CR2	NA
NS86	France	NS	3, 7	c.309C>G	p.H103Q	CR1,	H103Q/WT
				c.770C>T	p. S257L	CR2	WT/WT
NS92	Germany	NS	7	c.770C>T	p.S257L	CR2	WT/WT
NS135	Japan	NS	7	c.770C>T	p.S257L	CR2	NA
NS146	Spain	NS	7	c.770C>T	p.S257L	CR2	NA
NS199	Japan	NS	7	c.770C>T	p.S257L	CR2	NA
NS200	France	NS	7	c.770C>T	p.S257L	CR2	NA
NS215	Japan	NS	7	c.770C>T	p.S257L	CR2	NA
NS227	Japan	NS	7	c.770C>T	p.S257L	CR2	NA
NS256	Japan	NS	7	c.770C>T	p.S257L	CR2	NA
NS258	Japan	NS	7	c.770C>T	p.S257L	CR2	WT/WT
NS279	Japan	NS	7	c.776C>T	p.S259F	CR2	NA
NS210	France	NS	7	c.781C>G	p.P261A	CR2	WT/WT
NS205	France	CS[b]	7	c.782C>T	p.P261L	CR2	NA
NS209	France	CS[c]	7	c.786T>A	p.N262K[a]	CR2	WT/WT
NS222	Japan	NS	12	c.1279A>G	p.S427G[d]	CR3	WT/p.S427G
NS285	Japan	NS	17	c.1837C>G	p.L613V	CR3	NA

NS, Noonan syndrome; CS, Costello syndrome; WT, wild type; CR, conserved region; NA, not available.
*GenBank RefSeq: NM_002880.3 Nucleotide numbering reflects cDNA numbering with +1 corresponding to the A of the ATG translation initiation codon in the reference sequence, according to journal guidelines (www.hgvs.org/mutnomen). The initiation codon is codon 1.
[a]Novel mutation.
[b]Detailed clinical manifestations were not obtained.
[c]The patient died at 1 month.
[d]The mutation was previously identified in a patient with a therapy-related acute leukemia.

ASD (31%), arrhythmia (38%), and mitral valve anomaly (29%). Other observed clinical features were hyperelastic skin (58%), curly hair (47%), and cryptorchidism in males (50%). Coagulation defects were observed in two patients.

Four patients with *RAF1* mutations died before 5 years of age (Supp. Table S2). Patient NS39 were diagnosed as having cystic hygroma in the prenatal period and had suffered from neonatal hypertrophic cardiomyopathy. At 1 year of age, she contracted acute respiratory distress syndrome after having pneumonia and died of respiratory failure. Patient NS199 had been suspected to have achondroplasia because of short limbs. He was diagnosed as having NS at 3 years of age because of distinct facial features, growth failure, short stature, and hypertrophic cardiomyopathy. He had pneumonia without fever for a week and died suddenly at 5 years of age. Patient NS227 suffered from feeding difficulties, ectopic atrial tachycardia, as well as VSD and pulmonary hypertension. The patient died at 2 months of tachycardia (>200/min) and laryngeal edema.

Clinical manifestations in our patients with *RAF1* mutations were compared with those previously reported (Table 2). The high frequency of hypertrophic cardiomyopathy in our study (63%) was consistent with that observed in patients with *RAF1* mutations previously reported (77%). The frequency of ASD and that of mitral valve anomaly were similar to those of the previous studies. However, the frequency of PS in our study (47%) was higher than that previously reported (11%). Arrhythmia was less frequently observed in our patients with *RAF1* mutations (38 vs. 89%). The frequency of mental retardation (55%) was almost same as that of the previous studies (56%). Hyperelastic skin (58%) and coagulation defects (two cases) were also described in previously reported patients with *RAF1* mutations (24% and one case, respectively).

Phosphorylation State of Mutant RAF1 Proteins

RAF1 is a ubiquitously expressed RAF serine/threonine kinase, which regulates the RAS pathway. It has been shown that phosphorylation of serine, threonine, and tyrosine residues contributes to a conformational change of RAF1 protein and activation in growth factor stimulation [Mercer and Pritchard, 2003]. In the inactive state, phosphorylated S259 and S621 serve as binding sites for 14-3-3, leading to a closed confirmation [Dhillon et al., 2007]. Phosphorylation of S621 seems essential for RAF1 activation. In contrast, phosphorylation of serine 259 has been shown to have an inhibitory role in RAF1 activation. When cells are stimulated with growth factors, dephosphorylation of S259 by protein phosphatase 1 (PP1) and/or protein phosphatase 2A (PP2A) promotes the dissociation of 14-3-3 from RAF1, resulting in an activated conformation of RAF1 protein. For full activation, multiple residues, including S338, are phosphorylated and substrate of RAF1 enters the catalytic cleft in the CR3 kinase domain. Negative feedback from activated ERK results in the phosphorylation of S289, 296, and 301 [Dhillon et al., 2007].

To examine the phosphoryalation status of mutants observed in NS patients, we transfected constructs harboring WT *RAF1* cDNA and five mutants identified in NS patients. Immunoblotting was performed using four phospho-specific antibodies of RAF1 (Fig. 2A). We first analyzed the phosphorylation status of two phosphorylation sites, S259 and S621, using antibodies that recognize each site. Immunoblotting showed that phosphorylation of S259 was scarcely observed in cell lysates expressing p.S257L and p.N262K. In contrast, phosphorylation of S259 of p.H103Q, p.R191I, and p.S427G was similar to that in WT RAF1. To confirm this observation, immunoprecipitation was performed using an anti-Myc antibody, and phosphorylation levels at S259 were examined (Fig. 2B). Immunoprecipitated RAF1 mutants (p.S257L and p.N262K) were not phosphorylated at S259, confirming that these mutants had impaired phosphorylation of S259. The phosphorylation level of S621 in four mutants (p.H103Q, p.R191I, p.S257L, and p.N262K) was similar to that in WT (Fig. 2A), whereas that in cells expressing p.S427G was enhanced. Phosphorylation levels at S338 and S289/296/301 were similar to that in WT except for p.S427G (Fig. 2A).

Phosphorylation levels at S259, S289/296/301, S338, and S621 were shown to be enhanced in cells expressing p.S427G. The expression of p.S427G appeared enhanced and the band was

Table 2. Clinical Manifestations in *RAF1*-Positive Patients in This Study and Past Studies

	Present cohort (%)	NS with *RAF1* mutations (%)	LS with *RAF1* mutations (%)
Number of patients in total	17	35[a]	2
Perinatal abnormality			
Polyhydramnios	6/15 (40)	6/19 (32)	ND
Fetal macrosomia	5/11 (45)	6/20 (30)	ND
Growth and development			
Failure to thrive in infancy	10/12(83)	3	ND
Mental retardation	6/11 (55)	19/34 (56)	1
Outcome			
Died	4/17 (24)	2/11 (18)	ND
Craniofacial characteristics			
Relative macrocephaly	16/17 (94)	16/21 (76)	ND
Hypertelorism	14/15 (93)	20/21 (95)	2
Downslanting palpebral fissures	10/16 (63)	19/21 (90)	2
Ptosis	9/16 (56)	19/21 (90)	1
Epicanthal folds	12/14 (86)	12/21 (57)	1
Low-set ears	14/15 (93)	18/21 (86)	2
Skeletal characteristics			
Short stature	11/15 (73)	30/35 (86)	2
Short neck	14/15 (93)	21/31 (68)	2
Webbing of neck	13/16 (81)	25/30 (83)	2
Cardiac defects			
Hypertrophic cardiomyopathy	10/16 (63)	27/35 (77)	2
Atrial septal defect	5/16 (31)	11/35 (31)	0
Ventricular septal defect	3/17 (18)	3/35 (9)	0
Pulmonic stenosis	7/15 (47)	4/35 (11)	1
Patent ductus arteriosus	2/17 (12)	ND	ND
Mitral valve anomaly	5/17 (29)	8/32 (25)	2
Arrhythmia	6/16 (38)	8/9 (89)	ND
Others	TR 1, PH 1, atrioventricular valve dysplasia 1, valvular AS 1	polyvalvular dysplasia 2 pulmonary valve dysplasia 1, PFO 1, TOF 2, AS 1, right shaft deflection 1	
Skeletal/extremity deformity			
Cubitus valgus	2/9 (22)	7/22 (32)	2
Pectus deformity	5/13 (38)	20/31 (65)	2
Others		prominent finger pads 2	prominent finger pads 1
Skin/hair anomaly			
Curly hair	8/17 (47)	6/24 (25)	2
Hyperelastic skin	7/12 (58)	5/21 (24)	2
Café au lait spots	1/14 (7)	2/20 (10)	2
Lentigines	1/14 (7)	2/21 (10)	2
Naevus	3/15 (20)	9/22 (41)	0
Others	low posterior implantation 4, hyperpigmentation 3, redundant skin 3, sparse hair 2, sparse eyebrows 2, hemangioma 2	dry skin 3, sparse hair 3, sparse eyebrows 2, keratosis pilaris 2	
Genitalia	6/11 (55)	11/16 (69)	
Cryptorchidism	5/10 (50)	8/13 (62)	ND
Blood test abnormality			
Coagulation defects	2/11 (18)	1/4 (25)	ND

NS, Noonan syndrome; LS, LEOPARD syndrome; ND, not described; TR, tricuspid regurgitation; PH, pulmonary hypertension; AS, aortic stenosis; PFO, patent foramen ovale; TOF, tetralogy of Fallot.
[a]Includes affected family members. Clinical manifestations in 3, 21, and 11 NS patients with *RAF1* mutations were summarized from three reports [Ko et al., 2008; Pandit et al., 2007; Razzaque et al., 2007], respectively.

rather broad. However, Western blotting using antineomycin phosphoacetyltransferase antibody that recognizes the amount of plasmids introduced in cells showed that the transfection efficiency in cells expressing p.S427G was similar to that in cells expressing other mutants (Fig. 2A). These findings were consistently observed in three independent experiments. Recent studies have shown that autophosphorylation of S621 is required to prevent proteasome-mediated degradation [Noble et al., 2008]. To explore the possibility that p.S427G mutant is resistant to proteasome-mediated degradation, we examined the amount of WT RAF1 and p.S427G at 24, 48, and 72 hr after transfection in serum-starved or complete medium (Fig. 2C). The results showed that the expression of Myc-tagged RAF1 in cells expressing p.S427G was similar to that in WT RAF1, although multiple bands were observed, suggesting the hyperphosphorylation of the p.S427G mutant.

ELK Transactivation in Mutant RAF1 Proteins

To examine the effect on the downstream pathway of mutant RAF1, we introduced five RAF1 mutants into NIH3T3 cells and examined ELK transactivation (Fig. 2D). ELK is a transcription factor, which is phosphorylated by activated ERK and then binds the serum response element in the promoter of the immediate-early genes, including *C-FOS*. ELK transactivation was enhanced in cells expressing p.S257L, p.N262K, and p.S427G without any stimulation, suggesting that these mutants were gain-of-function



Figure 1. Facial appearance of patients with *RAF1* mutations. **a–f:** patients with p.S257L mutations. **a:** NS135; **b:** NS146; **c:** NS215; **d:** NS256; **e:** NS258 at 6 months; **f:** 2 years and 4 months; **g:** NS222 with p.S427G. [Color figure can be viewed in the online issue, which is available at www.interscience.wiley.com.]

mutations. ELK transactivation in cells expressing p.H103G and p.R191I was not enhanced.

Phosphorylation State, ERK Activation, and Binding to the Scaffolding Protein 14-3-3 in Mutations in the CR2 Domain

Previous studies as well as the present study showed that mutations in NS-associated *RAF1* mutations were clustered in the CR2 domain. We hypothesized that amino acid changes in the CR2 domain impaired phosphorylation of serine at 259. We additionally generated expression construct harboring p.S259F and p.P261A substitutions, and their phosphorylation status was examined using anti-pRAF1 (S259) antibody together with RAF1 WT, p.S257L, p.N262K, and p.S427G (Fig. 3A). The results showed that phosphorylated proteins were scarcely observed in p.S257L, p.S259F, p.P261A, and p.N262K. Phosphorylation of ERK p44/42 was determined using anti-p-ERK (p44/42) antibody. All mutations activated the downstream ERK without any stimulation. The level of ERK phosphorylation in cells expressing mutants was lower than that in those treated with epidermal growth factor (EGF), suggesting that the expression of p.S257L, p.S259F, p.P261A, and p.N262K resulted in a partial activation of ERK.

Anti-pRAF1 (S259) antibody was produced by immunizing rabbits with a synthetic phospho-peptide corresponding to residues surrounding Ser259 of human RAF1. To examine if this antibody was able to recognize phosphorylation at S259 when mutations such as S257L and N262K were introduced, we performed a solid-phase immunoassay using biotinylated peptides as per the manufacturer's recommendation (Mimotopes, Victoria, Australia; Supp. Methods). The result showed that at least in peptides, this antibody could recognize serine phosphorylation in amino acid 259 when mutations S257L and N262K were introduced (Fig. 3B). These results support the data in Figure 3A, suggesting that S259 was not phosphorylated in mutants in the CR2 domain.

To examine if the RAF1 mutants without S259 phosphorylation were able to bind to 14-3-3, we cotransfected three double mutants (WT/S621A, S257L/S621A, and N262K/S621A) with FLAG-tagged 14-3-3, and coimmunoprecipitation was performed using anti-Myc antibody (Fig. 3C). The result showed that the WT/S621A mutant bound 14-3-3. In contrast, p.S257L/S621A and



Figure 2. Analysis of phosphorylation status, degradation, and effect on downstream signaling in RAF1 mutants identified in this study. **A:** Phosphorylation status of wild-type (WT) RAF1 and mutants. Expression levels of RAF1 proteins and their phosphorylation levels were detected with different antibodies indicated in the figure. Transfection efficiency was measured using antineomycin phosphotransferase II (α-Neo) antibody. The arrow indicates the serine-phosphorylated expressed RAF1. **B:** Phosphorylation of S259 was confirmed by immunoprecipitation. Myc-tagged RAF1 was immunoprecipitated using anti-Myc antibody and the phosphorylation of S259 was determined. **C:** Time course experiments of WT RAF1 and p.S427G. The RAF1 protein was detected using anti-Myc antibody (clone 4A6; Millipore). FBS, fetal bovine serum. **D:** ELK transactivation in WT and mutants. Results are expressed as the means and standard deviations of mean values from triplicate samples. A significant increase in relative luciferase activity (RLA) was observed in cells transfected with p.S257L, p. N262K, and p.S427G, but not in cells transfected with p.H103Q or p.R191I. WT, wild-type; $^*P<0.01$ by Student's *t*-test.

p.N262K/S621A mutants did not bind 14-3-3, suggesting that the decreased phosphorylation of S259 prevented 14-3-3 binding. A similar result was obtained in the coimmunoprecipitation study using anti-FLAG antibody (Fig. 3D). These results showed that mutants in the CR2 domain impaired phosphorylation of S259, abrogated the binding to 14-3-3 and resulted in a partial activation of ERK.

Discussion

In this study, we identified eight different *RAF1* mutations in 18 patients: p.S257L in 11 patients and p.R191I, p.S259F, p.P261A, p.P261L, p.N262K, p.S427G, and p.L613V in one patient each. Sixteen patients were diagnosed as having NS, although we were not able to reevaluate 2 patients with Costello syndrome. Examination of detailed clinical manifestations in the present study and past studies showed that patients with *RAF1* mutations were associated with hypertrophic cardiomyopathy, arrhythmia, and mental retardation. Results from previous studies and the present study showed 41/52 (79%) mutations to be located in the CR2 domain (Fig. 3E). We first demonstrated that mutations in the CR2 domain had impaired phosphorylation of S259. This caused the impaired binding of RAF1 to 14-3-3, resulting in a partial activation of downstream ERK. These results suggest that dephosphorylation of S259 is the primary mechanism of activation of mutant RAF1 located in the CR2 domain.

Phosphorylation of S259 and subsequent binding to 14-3-3 have been shown to be important for suppression of RAF1 activity [Dhillon et al., 2007]. Light et al. [2002] examined the phosphorylation status at S259 in the p.S257L mutant. Their experiment showed that phosphorylation of S259 still existed in the p.S257L mutant. The mutant was not able to bind 14-3-3 [Light et al., 2002]. In contrast, our functional studies demonstrated that all four mutants located in the CR2 domain (p.S257L, p.S259F, p.P261A, and p.N262K) impaired phosphorylation of S259 and that two of them impaired binding of 14-3-3. Impaired binding to 14-3-3 was also shown in p.P261S mutant [Pandit et al., 2007]. The reason for the difference on S259 phosphorylation between the result by Light et al. [2002] and ours is unclear. Enhanced kinase activities of mutants, including p.S257L, p.P261S, p.P261A, and p.V263A, were demonstrated in a previous study [Razzaque et al., 2007]. Phosphorylation levels at S338 in p.S257L and p.N262K were not enhanced compared to that in WT RAF1 (Fig. 2A), suggesting that the activation mechanism in these mutants is different from that of the normal state upon RAS-GTP binding. Indeed, ERK activation was partial compared with that in cells after EGF treatment (Fig. 3A). These results suggest that the conformational change around S259 due to amino acid changes results in the decreased phosphorylation of S259 and that mutant



Figure 3. Phosphorylation of S259, binding to 14-3-3 and ERK activation of mutants located in the CR2 domain. **A:** Phosphorylation status of WT and mutants located in the CR2 domain. Phosphorylation of S259 was not observed in cells expressing p.S257L, p.S259F, p.P261A, and p.N262K. In order to examine the level of full activation of ERK, mock-transfected cells were treated with 10 ng/ml EGF. ERK activation was observed in cells expressing p.S257L, p.S259F, p.P261A, and p.N262K, but was weaker than those in cells expressing p.S427G and EGF-treated cells. The arrow indicates the serine-phosphorylated expressed RAF1. **B:** Epitope mapping of the anti-pRAF1 (S259) antibody using a solid-phase immunoassay. The antibody was able to recognize peptides with S257L or N262K mutations when S259 was phosphorylated, but was not able to recognize peptides without Ser259 phosphorylation. Results are expressed as the means and standard deviations of mean values from triplicate samples. **C:** Binding of RAF-1 to 14-3-3ζ. HEK293 cells were transfected with constructs harboring FLAG-tagged 14-3-3 and one construct of pUSE WT, p.S257L/p.S621A, or p.N262K/ p.S621A. Immunoprecipitation was performed using anti-Myc antibody, and 14-3-3 binding was determined by anti-FLAG antibody (upper panel). Phosphorylation of S259 and RAF1 expression were determined in cell lysates used for the immunoprecipitation (lower panel). The arrow indicates the band for 14-3-3. **D:** Binding of 14-3-3ζ to RAF-1. Immunoprecipitation was performed using anti-FLAG antibody and RAF1 binding was examined using anti-RAF1 antibody (upper panel). The binding of 14-3-3 to endogenous RAF1 was scarcely observed (lane 1, pUSE). Phosphorylation of S259 and RAF1 expression were determined using cell lysates used for the immunoprecipitation (lower panel). **E:** Domain organization and the distribution of mutations in RAF1 protein. The three regions conserved in all RAF proteins (conserved region [CR] 1, CR2, and CR3) are shown in pink. Mutations identified in this study are shown above the bar and those reported before [Ko et al. 2008; Pandit et al. 2007; Razzaque et al. 2007] are shown below the bar. Green squares indicate families with NS. Orange squares indicate patients with LEOPARD syndrome and the yellow square indicates a patient with hypertrophic cardiomyopathy.

RAF-1 then dissociates from 14-3-3; the substrate would thus be targeted to the catalytic domain in the CR3 domain (Fig. 4).

To highlight the clinical pictures of patients with *RAF1* mutations, clinical manifestations in 52 patients with *RAF1* mutations [Ko et al., 2008; Pandit et al., 2007; Razzaque et al., 2007], 172 patients with *PTPN11* mutations [Jongmans et al., 2005; Musante et al., 2003; Tartaglia et al., 2002; Zenker et al., 2004], 73 patients with *SOS1* mutations [Ferrero et al., 2008; Narumi et al., 2008; Roberts et al., 2007; Tartaglia et al., 2007; Zenker et al., 2007a] and 18 patients with *KRAS* mutations [Carta et al., 2006; Ko et al., 2008; Lo et al., 2008; Schubbert et al., 2006; Zenker et al., 2007b] are summarized in Table 3. The frequency of perinatal abnormalities was similar between patients with *RAF1* and *SOS1*. In contrast, the description of perinatal abnormalities was rare in patients with *PTPN11* and *KRAS* mutations. Growth failure and mental retardation were observed in 100 and 94% of NS with *KRAS* mutations, respectively. Growth failure and mental retardation were observed in 87 and 56% of patients with *RAF1* mutations, respectively. In contrast, those manifestations were less frequent (63 and 43%) in patients with *PTPN11* mutations. The frequency of mental retardation was lowest in patients with *SOS1* mutations (18%). We were unable to compare gene-specific features in craniofacial characteristics because such details were not described in the previous reports. As for skeletal characteristics, short stature was frequently manifested in patients with *RAF1* mutations (82%) followed by *KRAS* mutation-positive patients (71%). The association of short stature was lower in *PTPN11* mutation-positive and *SOS1* mutation-positive patients (56 and 38%, respectively). It is noteworthy that the association of hypertrophic cardiomyopathy was specifically high (73%) in *RAF1* mutation-positive patients. In contrast, hypertrophic cardiomyopathy was observed in 20% of clinically diagnosed Noonan



Figure 4. Schematic model of WT and mutant activation. **A:** In an inactive state, RAF1 is phosphorylated on S259 and S621 and is bound to 14-3-3. **B:** In growth-factor stimulation, the GTP-bound RAS binds to the CR1 domain of RAF1, which displaces 14-3-3. S259 is dephosphorylated by protein phosphatase 1 (PP1) and/or protein phosphatase 2A (PP2A). After RAF1 is recruited to the plasma membrane, phosphorylation of S338, Y341, T491, and S494 occurs. The phosphorylation of these residues is thought to be important for the full activation of RAF1. **C:** Mutants whose amino acid changes are located in the CR2 domain. It has been reported that S259 was phosphorylated by Akt and dephosphorylated by PP1 and/or PP2A. Amino acid changes in the CR2 domain would cause structural changes in the CR2 domain, leading to the access of PP2A to S259. Alternatively, Akt kinase would not be able to phosphorylate S259. S259 is dephosphorylated without stimulation and substrate(s) would be able to enter the kinase domain, leading to a partial activation. RBD, RAS-binding domain; CRD, cysteine-rich domain; KD, kinase domain; IH, isoform-specific hinge segment region. [Color figure can be viewed in the online issue, which is available at www.interscience.wiley.com.]

patients [van der Burgt 2007] and in 7, 10, and 17% of patients with *PTPN11*, *SOS1*, and *KRAS* mutations, respectively. These results strongly suggest that patients with *RAF1* mutations have a significantly higher risk of hypertrophic cardiomyopathy. Mitral valve abnormality and arrhythmia were also frequently observed in patients with *RAF1* mutations (27 and 56%, respectively). In summary, these results highlight specific manifestations of patients with *RAF1* mutations: high frequency of hypertrophic cardiomyopathy, septal defects of the heart, short stature, and less frequent PS (Supp. Fig. S1). The high frequency of heart defects would be associated with a high risk of sudden death in *RAF1* mutation-positive patients.

The present study is the first to identify p.S427G in a patient with NS. The same mutation has been reported in a patient with therapy-related acute myeloid leukemia [Zebisch et al., 2006]. The patient reported by Zebisch et al. [2006] first developed immature teratoma, yolk sack tumor, and embryonal testicular carcinoma. Thirty-five months after tumor resection and chemotherapy, the patient developed acute myeloid leukemia. Molecular analysis of *RAF1* revealed the de novo p.S427G mutation in leukemia cells and DNA from buccal epithelial cells [Zebisch et al., 2006]. Whether or not the patient had an NS phenotype was not mentioned. *RAF1* mutations have been rarely reported in malignant tumors. As far as we could determine, only six mutations, including p.P207S, p.V226I, p.Q335H, p.S427G, p.I448V, and p.E478K, have been identified in tumors and therapy-related leukemias [Pandit et al., 2007; Razzaque et al., 2007]. A previous study as well as our results showed that p.S427G mutant has transformation capacity [Zebisch et al., 2009], is resistant to apoptosis when introduced into NIH3T3 cells [Zebisch et al., 2009] and activates ERK and ELK transcription, suggesting that p.S427G is a gain-of-function mutation. We identified p.S427G in a familial case of NS. The mother and boy have not yet developed malignant tumors. Although no NS patients with *RAF1* mutations have developed malignant tumors, careful observation might be prudent in *RAF1* mutation-positive children.

We identified two novel mutations, p.R191I and p.N262K. p.R191I is located in the CR1, and arginine at amino acid position 191 is evolutionally conserved [Mercer and Pritchard, 2003]. Activation of ERK was not observed in cells expressing p.R191I. ELK transactivation was rather decreased; parental samples were not available. There is a possibility that this change is a polymorphism.

In conclusion, we identified *RAF1* mutations in 18 patients and detailed clinical manifestations in mutation-positive patients were examined. Our analysis of patients with mutations in *RAF1*, *PTPN11*, *SOS1*, and *KRAS* showed hypertrophic cardiomyopathy and short stature to be frequently observed in patients with *RAF1* mutations. Functional analysis revealed that dephosphorylation of S259 would be the essential mechanism for ERK activation in RAF1 mutations. Despite recent progress in molecular characterization of NS and related disorders, genetic causes in

Table 3. Clinical Manifestations in NS Patients with *RAF1*, *PTPN11*, *SOS1*, and *KRAS* Mutations

	RAF1[a] (%)	PTPN11[b] (%)	SOS1[c] (%)	KRAS[d] (%)
Total patients	52	172	73	18
Perinatal abnormality				
Polyhydramnios	12/34 (35)	ND	9/16 (56)	2
Fetal macrosomia	11/31 (35)	ND	9/15 (60)	ND
Growth and development				
Failure to thrive in infancy	13/15 (87)	35/56 (63)	ND	3/3 (100)
Mental retardation	25/45 (56)	71/164 (43)	12/67 (18)[e]	16/17 (94)[f]
Outcome				
Died	6/28 (21)	ND	ND	ND
Craniofacial characteristics				
Relative macrocephaly	32/38 (84)	ND	9/21 (43)[e]	9/11 (82)
Hypertelorism	34/36 (94)	15/28 (54)[e]	5/6 (83)	12/12 (100)
Downslanting palpebral fissures	29/37 (78)	19/28 (68)	20/22 (91)	9/12 (75)
Ptosis	28/37 (76)	18/29 (62)	19/24 (79)	10/15 (67)
Epicanthal folds	24/35 (69)	15/28 (54)	ND	2/9 (22)[e]
Low set ears	32/36 (89)	56/64 (88)	20/22 (91)	7/10 (70)
Skeletal characteristics				
Short stature	41/50 (82)	97/172 (56)[e]	22/58 (38)[e]	12/17 (71)
Short neck	35/46 (76)	15/29 (52)[e]	17/22 (77)	9/10 (90)
Webbing of neck	38/46 (83)	36/122 (30)[e]	3/6 (50)	7/14 (50)[e]
Cardiac defects				
Hypertrophic cardiomyopathy	37/51 (73)	10/135 (7)[e]	7/73 (10)[e]	3/18 (17)[e]
Septal defect	22/52 (42)	41/170 (24)[e]	17/73 (23)[e]	5/18 (28)
Atrial septal defect	16/51 (31)			4/18 (22)
Ventricular septal defect	6/52 (12)			1/18 (6)
Pulmonic stenosis	11/50 (22)	125/171 (73)[f]	53/73 (73)[f]	7/18 (39)
Patent ductus arteriosus	2/20 (10)	ND	ND	1/18 (6)
Mitral valve anomaly	13/49 (27)	ND	ND	3/18 (17)
Arrhythmia	14/25 (56)	ND	ND	ND
Skeletal/extremity deformity				
Cubitus valgus	9/31(29)	14/61 (23)	1/6 (17)	2/2 (100)
Pectus deformity	25/44 (57)	108/171 (63)	38/56 (68)	13/16 (81)
Skin/hair anomaly				
Curly hair	14/41 (34)	ND	15/22 (68)[f]	1/12 (8)
Hyperelastic skin	12/33 (36)	ND	1/6 (17)	3/12 (25)
Café au lait spots	3/34 (9)	ND	1/6 (17)	1/9 (11)
Lentigines	3/35 (9)	ND	ND	ND
Naevus	12/37 (32)	ND	ND	ND
Genitalia				
Cryptorchidism	13/23 (57)	75/138 (54)	22/39 (56)	4/11 (36)
Blood test abnormality				
Coagulation defects	3/15 (20)	46/90 (51)	14/66 (21)	2/9 (22)

ND, not described.
[a][Ko et al., 2008; Pandit et al., 2007; Razzaque et al., 2007]; and this study.
[b][Jongmans et al., 2005; Musante et al., 2003; Tartaglia et al., 2002; Zenker et al., 2004].
[c][Ferrero et al., 2008; Ko et al., 2008; Narumi et al., 2008; Roberts et al., 2007; Tartaglia et al., 2007; Zenker et al., 2007a].
[d][Carta et al., 2006; Ko et al., 2008; Lo et al., 2008; Schubbert et al., 2006; Zenker et al., 2007b].
[e]The frequency of the manifestation in patients with the gene was significantly lower compared with that observed in *RAF1*-positive patients ($P<0.05$ by Fisher's exact test).
[f]The frequency of the manifestation in patients with the gene was significantly higher compared with that observed in *RAF1*-positive patients ($P<0.05$ by Fisher's exact test).

approximately 30% of NS and related disorders remain unknown. Presently unknown genetic causes for mutation-negative NS and related disorders remain to be identified in molecules in future studies.

Acknowledgments

The authors wish to thank the patients and their families who participated in this study. We are grateful to physicians who referred the patients and to Kumi Kato and Miyuki Tsuda for technical assistance. This work was supported by Grants-in-Aids from the Ministry of Education, Culture, Sports, Science and Technology of Japan, Japan Society for the Promotion of Science, and The Ministry of Health Labour and Welfare to Y.M. and Y.A. and by an outstanding Senior Graduate Student award from Tohoku University Graduate School of Medicine to T.K.

References

Allanson JE, Hall JG, Hughes HE, Preus M, Witt RD. 1985. Noonan syndrome: the changing phenotype. Am J Med Genet 21:507–514.

Aoki Y, Niihori T, Kawame H, Kurosawa K, Ohashi H, Tanaka Y, Filocamo M, Kato K, Suzuki Y, Kure S, Matsubara Y. 2005. Germline mutations in HRAS proto-oncogene cause Costello syndrome. Nat Genet 37:1038–1040.

Aoki Y, Niihori T, Narumi Y, Kure S, Matsubara Y. 2008. The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders. Hum Mutat 29:992–1006.

Bentires-Alj M, Kontaridis MI, Neel BG. 2006. Stops along the RAS pathway in human genetic disease. Nat Med 12:283–285.

Brems H, Chmara M, Sahbatou M, Denayer E, Taniguchi K, Kato R, Somers R, Messiaen L, De Schepper S, Fryns JP, Cools J, Marynen P, Thomas G, Yoshimura A, Legius E. 2007. Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1-like phenotype. Nat Genet 39:1120–1126.

Carta C, Pantaleoni F, Bocchinfuso G, Stella L, Vasta I, Sarkozy A, Digilio C, Palleschi A, Pizzuti A, Grammatico P, Zampino G, Dallapiccola B, Gelb BD, Tartaglia M. 2006. Germline missense mutations affecting KRAS isoform B are associated with a severe Noonan syndrome phenotype. Am J Hum Genet 79:129–135.

Dhillon AS, von Kriegsheim A, Grindlay J, Kolch W. 2007. Phosphatase and feedback regulation of Raf-1 signaling. Cell Cycle 6:3–7.

Digilio MC, Conti E, Sarkozy A, Mingarelli R, Dottorini T, Marino B, Pizzuti A, Dallapiccola B. 2002. Grouping of multiple-lentigines/LEOPARD and Noonan syndromes on the PTPN11 gene. Am J Hum Genet 71:389–394.

Ferrero GB, Baldassarre G, Delmonaco AG, Biamino E, Banaudi E, Carta C, Rossi C, Silengo MC. 2008. Clinical and molecular characterization of 40 patients with Noonan syndrome. Eur J Med Genet 51:566–572.

Hennekam RC. 2003. Costello syndrome: an overview. Am J Med Genet C Semin Med Genet 117:42–48.

Jongmans M, Sistermans EA, Rikken A, Nillesen WM, Tamminga R, Patton M, Maier EM, Tartaglia M, Noordam K, van der Burgt I. 2005. Genotypic and phenotypic characterization of Noonan syndrome: new data and review of the literature. Am J Med Genet A 134A:165–170.

Ko JM, Kim JM, Kim GH, Yoo HW. 2008. PTPN11, SOS1, KRAS, and RAF1 gene analysis, and genotype–phenotype correlation in Korean patients with Noonan syndrome. J Hum Genet 53:999–1006.

Light Y, Paterson H, Marais R. 2002. 14-3-3 antagonizes Ras-mediated Raf-1 recruitment to the plasma membrane to maintain signaling fidelity. Mol Cell Biol 22:4984–4996.

Lo FS, Lin JL, Kuo MT, Chiu PC, Shu SG, Chao MC, Lee YJ, Lin SP. 2008. Noonan syndrome caused by germline KRAS mutation in Taiwan: report of two patients and a review of the literature. Eur J Pediatr 168:919–923.

Mendez HM, Opitz JM. 1985. Noonan syndrome: a review. Am J Med Genet 21:493–506.

Mercer KE, Pritchard CA. 2003. Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim Biophys Acta 1653:25–40.

Musante L, Kehl HG, Majewski F, Meinecke P, Schweiger S, Gillessen-Kaesbach G, Wieczorek D, Hinkel GK, Tinschert S, Hoeltzenbein M, Ropers HH, Kalscheuer VM. 2003. Spectrum of mutations in PTPN11 and genotype–phenotype correlation in 96 patients with Noonan syndrome and five patients with cardio-facio-cutaneous syndrome. Eur J Hum Genet 11:201–206.

Narumi Y, Aoki Y, Niihori T, Sakurai M, Cave H, Verloes A, Nishio K, Ohashi H, Kurosawa K, Okamoto N, Kawame H, Mizuno S, Kondoh T, Addor MC, Coeslier-Dieux A, Vincent-Delorme C, Tabayashi K, Aoki M, Kobayashi T, Guliyeva A, Kure S, Matsubara Y. 2008. Clinical manifestations in patients with SOS1 mutations range from Noonan syndrome to CFC syndrome. J Hum Genet 53:834–841.

Niihori T, Aoki Y, Narumi Y, Neri G, Cave H, Verloes A, Okamoto N, Hennekam RC, Gillessen-Kaesbach G, Wieczorek D, Kavamura MI, Kurosawa K, Ohashi H, Wilson L, Heron D, Bonneau D, Corona G, Kaname T, Naritomi K, Baumann C, Matsumoto N, Kato K, Kure S, Matsubara Y. 2006. Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome. Nat Genet 38:294–296.

Noble C, Mercer K, Hussain J, Carragher L, Giblett S, Hayward R, Patterson C, Marais R, Pritchard CA. 2008. CRAF autophosphorylation of serine 621 is required to prevent its proteasome-mediated degradation. Mol Cell 31:862–872.

Pandit B, Sarkozy A, Pennacchio LA, Carta C, Oishi K, Martinelli S, Pogna EA, et al. 2007. Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. Nat Genet 39:1007–1012.

Razzaque MA, Nishizawa T, Komoike Y, Yagi H, Furutani M, Amo R, Kamisago M, Momma K, Katayama H, Nakagawa M, Fujiwara Y, Matsushima M, Mizuno K, Tokuyama M, Hirota H, Muneuchi J, Higashinakagawa T, Matsuoka R. 2007. Germline gain-of-function mutations in RAF1 cause Noonan syndrome. Nat Genet 39:1013–1017.

Reynolds JF, Neri G, Herrmann JP, Blumberg B, Coldwell JG, Miles PV, Opitz JM. 1986. New multiple congenital anomalies/mental retardation syndrome with cardio-facio-cutaneous involvement—the CFC syndrome. Am J Med Genet 25:413–427.

Roberts AE, Araki T, Swanson KD, Montgomery KT, Schiripo TA, Joshi VA, Li L, Yassin Y, Tamburino AM, Neel BG, Kucherlapati RS. 2007. Germline gain-of-function mutations in SOS1 cause Noonan syndrome. Nat Genet 39: 70–74.

Rodriguez-Viciana P, Tetsu O, Tidyman WE, Estep AL, Conger BA, Cruz MS, McCormick F, Rauen KA. 2006. Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome. Science 311:1287–1290.

Schubbert S, Zenker M, Rowe SL, Boll S, Klein C, Bollag G, van der Burgt I, Musante L, Kalscheuer V, Wehner LE, Nguyen H, West B, Zhang KY, Sistermans E, Rauch A, Niemeyer CM, Shannon K, Kratz CP. 2006. Germline KRAS mutations cause Noonan syndrome. Nat Genet 38:331–336.

Tartaglia M, Kalidas K, Shaw A, Song X, Musat DL, van der Burgt I, Brunner HG, Bertola DR, Crosby A, Ion A, Kucherlapati RS, Jeffery S, Patton MA, Gelb BD. 2002. PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity. Am J Hum Genet 70: 1555–1563.

Tartaglia M, Mehler EL, Goldberg R, Zampino G, Brunner HG, Kremer H, van der Burgt I, Crosby AH, Ion A, Jeffery S, Kalidas K, Patton MA, Kucherlapati RS, Gelb BD. 2001. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet 29:465–468.

Tartaglia M, Pennacchio LA, Zhao C, Yadav KK, Fodale V, Sarkozy A, Pandit B, Oishi K, Martinelli S, Schackwitz W, Ustaszewska A, Martin J, Bristow J, Carta C, Lepri F, Neri C, Vasta I, Gibson K, Curry CJ, Siguero JP, Digilio MC, Zampino G, Dallapiccola B, Bar-Sagi D, Gelb BD. 2007. Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome. Nat Genet 39:75–79.

van der Burgt I. 2007. Noonan syndrome. Orphanet J Rare Dis 2:4.

Zebisch A, Haller M, Hiden K, Goebel T, Hoefler G, Troppmair J, Sill H. 2009. Loss of RAF kinase inhibitor protein is a somatic event in the pathogenesis of therapy-related acute myeloid leukemias with C-RAF germline mutations. Leukemia 23:1049–1053.

Zebisch A, Staber PB, Delavar A, Bodner C, Hiden K, Fischereder K, Janakiraman M, Linkesch W, Auner HW, Emberger W, Windpassinger C, Schimek MG, Hoefler G, Troppmair J, Sill H. 2006. Two transforming C-RAF germ-line mutations identified in patients with therapy-related acute myeloid leukemia. Cancer Res 66:3401–3408.

Zenker M, Buheitel G, Rauch R, Koenig R, Bosse K, Kress W, Tietze HU, Doerr HG, Hofbeck M, Singer H, Reis A, Rauch A. 2004. Genotype–phenotype correlations in Noonan syndrome. J Pediatr 144:368–374.

Zenker M, Horn D, Wieczorek D, Allanson J, Pauli S, van der Burgt I, Doerr HG, Gaspar H, Hofbeck M, Gillessen-Kaesbach G, Koch A, Meinecke P, Mundlos S, Nowka A, Rauch A, Reif S, von Schnakenburg C, Seidel H, Wehner LE, Zweier C, Bauhuber S, Matejas V, Kratz CP, Thomas C, Kutsche K. 2007a. SOS1 is the second most common Noonan gene but plays no major role in cardio-facio-cutaneous syndrome. J Med Genet 44:651–656.

Zenker M, Lehmann K, Schulz AL, Barth H, Hansmann D, Koenig R, Korinthenberg R, Kreiss-Nachtsheim M, Meinecke P, Morlot S, Mundlos S, Quante AS, Raskin S, Schnabel D, Wehner LE, Kratz CP, Horn D, Kutsche K. 2007b. Expansion of the genotypic and phenotypic spectrum in patients with KRAS germline mutations. J Med Genet 44:131–135.

Medical genetics

Familial cases of atypical clinical features genetically diagnosed as LEOPARD syndrome (multiple lentigines syndrome)

Harunosuke Kato[1], MD, Rie Yoshida[2], MD, PhD, Katsuhiko Tsukamoto[3], MD, Hirotaka Suga[1], MD, Hitomi Eto[1], MD, Takuya Higashino[1], MD, Jun Araki[1], MD, Tsutomu Ogata[2], MD, and Kotaro Yoshimura[1], MD

[1]Department of Plastic Surgery, University of Tokyo School of Medicine, Tokyo, [2]Department of Endocrinology and Metabolism, National Research Institute for Child Health and Development, Tokyo, and [3]Department of Dermatology, Yamanashi Prefectural Central Hospital, Yamanashi, Japan

Correspondence
Kotaro Yoshimura, MD
Department of Plastic Surgery
University of Tokyo School of Medicine,
7-3-1, Hongo
Bunkyo-Ku
Tokyo 113-8655
Japan
E-mail: yoshimura-pla@h.u-tokyo.ac.jp

Summary

Five familial cases exhibited ephelides-like multiple lentigines, and we examined three of them, a mother and two sons. All three patients presented with small dark-brown maculae on the face and neck and electrocardiographic abnormalities. These findings sufficed to fulfill the criteria for LEOPARD syndrome (multiple lentigines syndrome), although they lacked five of seven major clinical features. However, the family members presented with a webbed neck and pectus excavatum, which are more frequently seen in Turner or Noonan syndrome. Histological examination of the lentigines revealed slightly elongated rete ridges, a hyperpigmented basal layer, and melanophages in the papillary dermis. Direct sequencing of the patients' genomic DNA revealed that all three had a consistent missense mutation [c.1403C > T (p.T468M)] in the *PTPN11* gene, confirming LEOPARD syndrome with an atypical phenotype. It was suggested that LEOPARD syndrome shows a diverse phenotype but its diagnosis can be verified by mutation analysis.

Introduction

In 1936, Zeisler and Becker[1] reported on a 24-year-old female with multiple lentigines scattered on her body, pectus carinatum, ocular hypertelorism, and mandibular prognathism, which was later named LEOPARD syndrome (LS) by Gorlin *et al.*[2] LEOPARD is an acronym for the major features that characterize the syndrome: multiple *L*entigines, *E*lectrocardiographic conduction defects, *O*cular hypertelorism, *P*ulmonary stenosis, genital *A*bnormality, *R*etardation of growth, and sensorineural *D*eafness. LS is an autosomal dominant disorder that has been presented not only by dermatologists, but also by other specialists,[3–8] and is also called multiple lentigines syndrome.[2,9] The life-threatening problems in LS patients are hypertrophic cardiomyopathy and malignant tumors.[10,11]

Missense mutations in exons 7, 12, and 13 of the protein-tyrosine phosphatase, nonreceptor type 11 (PTPN11) gene, which is located on chromosome 12q24.1 and encodes the protein tyrosine phosphatase SHP2, have been found in LS;[10,12,13] all the mutations are located at the catalytic cleft of the *PTPN11* protein.[14] The SHP2 protein plays an important role in several signal transduction pathways involving several cytokines and hormones, with a particular role in the RAS-mitogen activated protein kinase pathway.[15–17] Thus, although genetic testing is not commonly performed, it is helpful for confirming a diagnosis and differentiating LS from similar diseases, such as Peutz-Jeghers syndrome, Carney syndrome, Noonan syndrome, and Turner syndrome.

We describe a family with members exhibiting multiple lentigines with less-frequent symptoms, such as a webbed neck (pterygium colli) and pectus excavatum (trichterbrust), who were genetically diagnosed as having LS.

Case report

The family consisted of three generations (Fig. 1). In the 1st generation, there were two sisters. The elder sister (70-year-old) had multiple dark-brown lentigines, mainly on the face (similar appearance to ephelides), a webbed

International Journal of Dermatology 2010, **49**, 1146–1151



Figure 1 Family pedigree. Two family members in the 1st generation (the mother and mother's younger sister) and all three members in the 2nd generation (two sons and one daughter) presented with multiple lentigines (red). Multiple lentigines were not noted in the father and first brother's sons. Fa, father; Mo, mother; FB, first brother; SB, second brother; Si, sister

neck, and pectus excavatum without a short stature (Fig. 2). She had two sons and one daughter (the 2nd generation) and did not marry consanguineously. Her husband already died of lung cancer at the age of 64. The younger sister (65-year-old) had multiple lentigines and no children before she died.

The second brother of the 2nd generation (41-year-old) presented with small, dark brown, irregularly pigmented maculae 1 to 4 mm in size on the face and neck, including the vermillion, but not involving the oral and orbital mucosa (Fig. 2). The maculae had been present since birth, and new lesions gradually developed until his 20s and darkened with age. He also presented with other features, such as a webbed neck with a lower hairline and pectus excavatum. Electrocardiography indicated arterial fibrillation, ventricular extrasystole, tachycardia, and left anterior hemiblock. Echocardiography showed mild mitral valve regurgitation, tricuspid valve regurgitation, aorta dilation, and left ventricular dilation. Pulmonary stenosis was not found. Gastrointestinal and colon fibroscopy did not detect polyposis or any other abnormalities. Levels of thyroid stimulating hormone, free thyroxine, and free triiodothyronine were normal. Chromosome analysis showed a normal 46, XY karyotype in all the 50 peripheral lymphocytes examined. The first brother (44-year-old) (Fig. 2) and a sister (39-year-old) of the 2nd generation showed almost the same physical findings. Only the second brother had nevus spilus-like maculae on the back and left arm, but neurofibroma did not present in any of the family members. Bilateral blepharoptosis was noted also only by the second brother, although there was no accompanying exophthalmus or ocular hyperterolism.

The first brother of the 2nd generation has two sons (3rd generation), aged 6 and 5 years, with no symptoms suggesting LS, although multiple lentigines may appear in



Figure 2 Photographs of three family members. All three members (the mother, the first brother and the second brother) presented with multiple small brown maculae on the face and neck, a webbed neck, and pectus excavatum

Table 1 Summarized clinical manifestations of five family members

Manifestations			Fa	Mo	FB	SB	Si
Genome	Missense mutation in the PTPN11 gene		N/A	+	+	+	N/A
L	Multiple *L*entigines		–	+	+	+	+
E	*E*CG abnormalities		N/A	+	+	+	+
O	*O*cular hypertelorism		–	–	–	–	–
P	*P*ulmonary stenosis		N/A	N/A	N/A	–	N/A
A	*A*bnormal genetalia	Cryptorchidism	–	–	–	–	–
R	*R*etardation of growth		–	–	–	–	–
D	Sensorineural *D*eafness		–	–	–	–	–
Skin	Cafè-au-lait spots		–	+	+	+	N/A
	Neurofibromatosis		–	–	–	–	–
	Curly, coarse hair		–	–	–	–	–
Ear	Low-set ear		+	+	+	+	N/A
Eye (Eyelids)	Light-colored irises		–	–	–	–	N/A
	Blepharoptosis		+	+	+	+	+
	Epicanthal folds		–	–	+	+	N/A
Cardiovascular	Congenital heart defects		N/A	N/A	N/A	+	N/A
	Hypertrophic cardiomyopathy		N/A	N/A	N/A	–	N/A
Skeletal	Short stature		–	–	–	–	–
	Pectus excavatum and/or carinatum		–	+	+	+	+
	Vertebral anomalies	Scoliosis	–	–	–	–	–
	Cubitus valgus		–	–	–	–	–
Hematological	Bleeding diathesis (von Willebrand disease, factors XI and XII deficiency)		–	–	–	–	–
	Thrombocytopenia		–	–	–	–	–
	Leukemia		–	–	–	–	–
Others	Webbed neck with low posterior hairline		–	+	+	+	+
	Malocclusion		–	+	+	+	N/A
	Lymphatic disorder	Lymphedema	–	–	–	–	–
	Triangular facies		–	–	–	–	N/A
	Feeding difficulties		–	–	–	–	–
	Cryptorchidism		–	–	–	–	–
	Mental retardation		–	–	–	–	–
	Sexual infantilism		–	–	–	–	–

ECG, electrocardiogram; Fa, father; Mo, mother; FB, first brother; SB, second brother; Si, sister.

the future. The second brother and a sister do not have any children.

There was no abnormality of the external genitalia or urinary organs in any family members. Intelligence, mental development, and hearing were also normal. The clinical data are summarized in Tables 1 and 2.

Human tissue analyses were performed in compliance with the Declaration of Helsinki Principles. Peripheral blood samples were taken from the mother (1st generation) and both brothers (2nd generation) using an ethics committee-approved protocol for genomic DNA analyses after each patient provided informed consent. Photo release consent was also obtained from each patient. Leukocyte genomic DNA was amplified by PCR for the 15 exons and flanking introns of *PTPN11* and was subjected to direct sequencing from both directions using a CEQ 8000 autosequencer (Beckman Coulter, Fullerton, CA, USA). The primer sequences and PCR conditions were

Table 2 Characteristic manifestations of LEOPARD and Noonan syndrome

Manifestations	Fa	Mo	FB	SB	Si
LEOPARD Multiple Lentigines	–	+	+	+	+
Sensorineural Deafness	–	–	–	–	–
ECG abnormalities Noonan	N/A	+	+	+	+
Facial dysmorphism (e.g. Ocular hypertelorism)	N/A	N/A	N/A	–	N/A
Cardiovascular defects (e.g Pulmonary stenosis)	–	–	–	–	–
Abnormal genetalia (e.g Cryptochidism)	–	–	–	–	–
Retardation of growth (e.g. Short stature)	–	–	–	–	–
Mental retardation	–	–	–	–	–
Webbed neck	–	+	+	+	+
Pectus excavatum	–	+	+	+	+
Hematologic abnormalities (e.g. Leukemia)	–	–	–	–	–

Fa, father; Mo, mother; FB, first brother; SB, second brother; Si, sister.



Figure 3 Electrochromatograms for the three family members. The PTPN11 mutation (Thr468Pro, 1403AfiC) was detected in genomic DNA from the leukocytes of the three patients

described previously.[18] To confirm any mutations, three independent PCR products were examined. Mutation analysis indicated a heterozygous C > T substitution at position c.1403 in *PTNP11* exon 12 in all the three subjects, resulting in the missense mutation Thr468Met (Fig. 3), which is one of the known mutations for LS. This mutation is located at the catalytic cleft of the PTP domain and impairs phosphatase activity of SHP2.[19]

A skin biopsy of a pigmented facial lesion was taken from the second brother (2nd generation). The biopsied sample was processed for HE staining and Fontana-Masson ammoniac silver staining. Histological examination of the lentigine specimen (Fig. 4) revealed that epidermal rete ridges were slightly elongated and basal layer of the epidermis were hyperpigmented with increased numbers of melanocytes. No nevus cells were observed. Deposition of melanophages was slightly detected in the top region of the dermal papillae, and we observed moderate infiltration of lymphocytes into the epidermis and hair follicle epithelium.



Figure 4 Histological examination of the biopsy specimen from the face of the second brother. Top: Histological examination of a pigmented macule demonstrated slightly elongated rete ridges and epidermal hypermelanosis using (Hematoxylin-Eosin staining. ×100; scale bar = 200 μm). Bottom: Higher magnification of the section revealed a hyperpigmented basal layer, incresed numbers of melanocytes without nest formation, and melanophages in the papillary dermis. (Masson-fontana ammoniac silver staining ×200; scale bar = 100 μm.)

Discussion

There are many reports in the literature of multiple lentigines associated with other symptoms, including Neurofibromatosis–Noonan syndrome,[20] Watson syndrome,[21] centrofacial lentiginosis,[22] inherited patterned lentiginosis,[23] Carney complex,[24] Peutz–Jeghers syndrome,[25] Laugier–Hunziker–Baran syndrome, and Cronkhite–Canada syndrome. In our cases, ephelides-like lentigines were spread predominantly on the face and neck without eruptions on the oral mucosa, and neither neurofibroma nor schwannoma were seen. Intestinal polyposis, myxoma, or endocrine dysfunction was not noted. However, our cases also lacked many major manifestations associated with LS; none of the patients exhibited ocular hypertelorism, pulmonary stenosis, abnormal genitalia, growth retardation, or sensorineural deafness. On the other hand, a webbed neck and pectus excavatum, which are less frequent in LS[9,26] and frequently seen in Noonan syndrome and Turner syndrome,[27] were noted.

LEOPARD syndrome has been reported to present with extremely variable phenotypes. Voron *et al.*[9] grouped the LS features into the following nine categories: cutaneous abnormalities, cardiac abnormalities, genitourinary abnormalities, endocrine findings, neurogenic defects, cephalofacial dysmorphism, short stature, skeletal anomalies, and familial history consistent with an autosomal dominant

mode of inheritance. Voron also proposed minimal diagnostic criteria for LS: at least two other features must be present in cases with multiple lentigines, whereas a diagnosis of LS may be made in cases with family history and three other major features despite an absence of multiple lentigines.[9] In our cases, three other features (cardiac and skeletal abnormalities and family history) were present in addition to multiple lentigines, but only two (multiple lentigines and ECG abnormality) of the seven major clinical manifestations advocated by Gorlin *et al.*[2] were noted. Therefore, careful differentiation from Noonan syndrome is needed because most of the clinical features of LS, such as heart defects, growth retardation, and facial dysmorphism, overlap with those of Noonan syndrome. Noonan syndrome presents as a Turner-like phenotype, such as short stature, cephalofacial dysmorphism, webbed neck, skeletal anomalies, and genitourinary and cardiac abnormalities, particularly pulmonary valve stenosis, although Noonan syndrome has a normal karyotype.[28]

Both LS and Noonan syndrome are known to be caused by heterozygous germline missense mutations in the PTPN11 gene. Approximately 85% of the patients with a definite diagnosis of LS have a missense mutation in the PTPN11 gene,[10] and mutations in the PTPN11 gene are also seen in roughly 50% of Noonan syndrome cases.[27,29] However, it was recently established by analyzing accumulated genetic data of LS and Noonan syndrome that the mutations in LS and Noonan syndrome are almost mutually exclusive.[14,30,31] In Noonan syndrome, PTPN mutations are detected at 33–60%,[27,30] and are recurrent and clustered mostly in exons 3, 7, 8, and 13.[12,27] Noonan syndrome mutations are recognized as gain-of-function mutations, while LS mutations were identified as having dominant negative, not activating, effects.[32] The most frequently (approximately 90%) reported PTPN11 mutations in LS are located in exons 7 (Tyr279Cys) and 12 (Thr468Met),[30] the latter of which was detected in all three family members examined here. In addition, to our knowledge, Thr468Met has never been detected in NS syndrome.[27,33] Taken together with the clinical finding that the three familial patients sufficed Voron's minimal diagnostic criteria for LS, we diagnosed them as LS.

It has been reported that there are typically two histological types of lentigines seen in LS patients:[9,26] melanocytic nevi and lentigo simplex. The biopsy specimen from our case exhibited histological features compatible with the latter, a lack of nevus cells and the presence of epidermal hypermelanosis.

In conclusion, three familial cases presented with ECG abnormalities and multiple lentigines on the face and neck, lacked most of other major features of LS, and exhibited a webbed neck and pectus excavatum. Genetic testing revealed that all of the patients carry a consistent germline missense mutation (Thr468Met, 1403C → T) in the exon 12 of PTPN11 gene, which suggested the diagnoses of LS.

Acknowledgment

The authors acknowledge Ms. Ayako Kurata for her technical assistance for the histological assessment. There is no funding to declare in this study.

References

1 Zeisler EP, Beker SW. Generalized Lentigo. *Arch Dermatol. Syph.* 1942; 45: 109–125.
2 Gorlin RJ, Anderson RC, Blaw M. Multiple lentigines syndrome. *Am J Dis Child* 1969; 117: 652–662.
3 Rees JR, Ross FG, Keen G. Lentiginosis and left atrial myxoma. *Br. Heart J.* 1973; 35: 874–876.
4 Swanson SL, Santen RJ, Smith DW. Multiple lentigines syndrome. New findings of hypogonadotropism hyposmia and unilateral renal agenesis. *J Pediatr* 1971; 78: 1037–1039.
5 MacEwen GD, Zaharko W. Multiple lentigines syndrome: a case report of a rare familial syndrome with orthopedic considerations. *Clin Orthop Relat Res* 1973; 97: 34–37.
6 Poznanski AK, Stern AM, Gall JC. Skeletal anomalies in genetically determined congenital heart disease. *Radiol Clin North Am* 1971; 9: 435–458.
7 Józwiak S, Schwartz RA, Janniger CK. LEOPARD syndrome (cardiocutanous lentiginosis syndrome). *Cutis* 1996; 57: 208–214.
8 Coppin BD, Temple IK. Multiple lentigines syndrome (LEOPARD syndrome or progressive cardiomyopathic lentiginosis). *J Med Genet* 1997; 34: 582–586.
9 Voron DA, Hatfield HH, Kalkhoff RK. Multiple lentigines syndrome. Case report and review of the literature. *Am J Med* 1976; 60: 447–456.
10 Sarkozy A, Digilio MC, Dallapiccola B. Leopard syndrome. *Orphanet. J. Rare Dis.* 2008; 3: 13.
11 Woywodt A, Welzel J, Haase H, *et al.* Cardiomyopathic lentiginosis/LEOPARD syndrome presenting as sudden cardiac arrest. *Chest* 1998; 113: 1415–1417.
12 Digilio MC, Conti E, Sarkozy A, *et al.* Grouping of multiple-lentigines/LEOPARD and Noonan syndromes on the PTPN11 gene. *Am J Hum Genet* 2002; 71: 389–394.
13 Digilio MC, Sarkozy A, de Zorzi A, *et al.* LEOPARD syndrome: clinical diagnosis in the first year of life. *Am. J. Med. Genet. A* 2006; 140: 740–746.
14 Gelb BD, Tartaglia M. Noonan syndrome and related disorders: dysregulated RAS-mitogen activated protein kinase signal transduction. *Hum Mol Genet.* 2006; 15(Spec No 2): R220–226.

15 Tartaglia M, Mehler EL, Goldberg R, *et al.* Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. *Nat Genet* 2001; 29: 465–468.
16 Legius E, Schrander-Stumpel C, Schollen E, *et al.* PTPN11 mutations in LEOPARD syndrome. *J Med Genet* 2002; 39: 571–574.
17 Sarkozy A, Conti E, Digilio MC, *et al.* Clinical and molecular analysis of 30 patients with multiple lentigines LEOPARD syndrome. *J Med Genet* 2004; 41: e68.
18 Yoshida R, Hasegawa T, Hasegawa Y, *et al.* Protein-tyrosine phosphatase, nonreceptor type 11 mutation analysis and clinical assessment in 45 patients with Noonan syndrome. *J Clin Endocrinol Metab* 2004; 89: 3359–3364.
19 Hanna N, Montagner A, Lee WH, *et al.* Reduced phosphatase activity of SHP-2 in LEOPARD syndrome: consequences for PI3K binding on Gab1. *FEBS Lett* 2006; 580: 2477–2482.
20 Bertola DR, Pereira AC, Passetti F, *et al.* Neurofibromatosis-Noonan syndrome: molecular evidence of the concurrence of both disorders in a patient. *Am J Med Genet* 2005; 136: 242–245.
21 Watson GH. Pulmonary stenosis, cafe au lait spots, and dull intelligence. *Arch Dis Child* 1967; 42: 303–307.
22 Dociu I, Galaction-Nitelea O, Sirjita N, *et al.* Centrofacial lentiginosis. A survey of 40 cases. *J Dermatol* 1976; 94: 39–43.
23 O'Neill JF, James WD. Inherited patterned lentiginosis in blacks. *Arch Dermatol* 1989; 125: 1231–1235.
24 Uriger CA, Headington JT. Psammomatous melanotic schwannnoma. A new cutaneous marker for Carney's complex. *Arch Dermatol* 1993; 129: 202–204.
25 Yamada K, Matsukawa A, Hori Y, *et al.* Ultrastructural studies on pigmented macules of Peutz-Jeghers syndrome. *J Dermatol* 1981; 8: 367–377.
26 Rodríguez-Bujaldón A, Vazquez-Bayo C, Jimenez-Puya R, *et al. LEOPARD syndrome: what are café noir spots? Pediatr Dermatol* 2008; 25: 444–448.
27 Tartaglia M, Gelb BD. Noonan syndrome and related disorders: genetics and pathogenesis. *Annu. Rev. Genomics Hum. Genet.* 2005; 6: 45–68.
28 Noonan JA. Hypertelorism with Turner phenotype. A new syndrome with associated congenital heart disease. *Am J Dis Child* 1968; 116: 373–380.
29 Sarkozy A, Conti E, Seripa D, *et al.* Correlation between PTPN11 gene mutations and congenital heart defects in Noonan and LEOPARD syndromes. *J Med Genet* 2003; 40: 704–708.
30 Ogata T, Yoshida R. PTPN11 mutations and genotype-phenotype correlations in Noonan and LEOPARD syndromes. *Pediatr. Endocrinol. Rev.* 2005; 2: 669–674.
31 Laux D, Kratz C, Sauerbrey A. Common acute lymphoblastic leukemia in a girl with genetically confirmed LEOPARD syndrome. *J Pediatr Hematol Oncol* 2008; 30: 602–604.
32 Kontaridis MI, Swanson KD, David FS, *et al.* PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects. *J Biol Chem* 2006; 281: 6785–6792.
33 Martinelli S, Torreri P, Tinti M, *et al.* Diverse driving forces underlie the invariant occurrence of the T42A, E139D, I282V and T468M SHP2 amino acid substitutions causing Noonan and LEOPARD syndromes. *Hum Mol Genet* 2008; 17: 2018–2029.

PEDIATRICS INTERNATIONAL Official Journal of the Japan Pediatric Society

Pediatrics International (2010) **52**, 547–550 doi: 10.1111/j.1442-200X.2010.03090.x

Original Article

1p36 deletion syndrome associated with Prader–Willi-like phenotype

Yu Tsuyusaki,[1] Hiroshi Yoshihashi,[1] Noritaka Furuya,[1] Masanori Adachi,[2] Hitoshi Osaka,[3] Kayono Yamamoto[4] and Kenji Kurosawa[1]

Divisions of [1]Medical Genetics, [2]Endocrinology and Metabolism, and [3]Neurology, Kanagawa Children's Medical Center, Yokohama, and [4]Department of Genetic Counseling, Graduate School of Humanities and Sciences, Ochanomizu University, Tokyo, Japan

Abstract ***Background***: 1p36 deletion syndrome is one of the most common subtelomeric deletion syndromes, characterized by moderate to severe mental retardation, characteristic facial appearance, hypotonia, obesity, and seizures. The clinical features often overlap with those of Prader–Willi syndrome (PWS). To elucidate the phenotype–genotype correlation in 1p36 deletion syndrome, two cases involving a PWS-like phenotype were analyzed on molecular cytogenetics.

Methods: Two patients presenting with the PWS-like phenotype but having negative results for PWS underwent fluorescence *in situ* hybridization (FISH). The size of the chromosome 1p36 deletions was characterized using probes of BAC clones based on the University of California, Santa Cruz (UCSC) Genome Browser.

Results: PWS was excluded on FISH and methylation-specific polymerase chain reaction. Subsequent FISH using the probe D1Z2 showed deletion of the 1p36.3 region, confirming the diagnosis of 1p36 deletion syndrome. Further analysis characterized the 1p36 deletions as being located between 4.17 and 4.36 Mb in patient 1 and between 4.89 and 6.09 Mb in patient 2.

Conclusion: Patients with 1p36 deletion syndrome exhibit a PWS-like phenotype and are therefore probably underdiagnosed. The possible involvement of the terminal 4 Mb region of chromosome 1p36 in the PWS-like phenotype is hypothesized.

Key words 1p36 deletion syndrome, chromosome, fluorescence *in situ* hybridization, obesity, Prader–Willi-like phenotype.

The terminal deletion of chromosome 1p36 is a newly recognized syndrome with multiple congenital anomalies and mental retardation.[1–4] The prevalence is estimated to range from 1 in 5000 to 1 in 10 000.[1,5] The most frequent clinical findings are moderate–severe mental retardation, facial characteristics including deep-set eyes and pointed chin, hypotonia, and seizures. The deletion size varies in each family and appears to be correlated with the clinical complexity as a result of haploinsufficiency of different genes,[6,7] but most breakpoints cluster at 4.0–4.5 Mb from the telomere (1pter). Some clinical manifestations of the syndrome overlap with those of Prader–Willi syndrome (PWS). Recently, a PWS-like phenotype has been described in patients with monosomy 1p36,[8] maternal uniparental disomy 14 (upd[14]mat),[9,10] and chromosome 6q16 deletion.[11] The common clinical features are global developmental delay, hypotonia, obesity, several craniofacial anomalies, hyperphagia, and behavioral problems.

Here, we describe two cases of 1p36 deletion syndrome in patients who were provisionally diagnosed with PWS, and elucidate the phenotype–genotype correlation in 1p36 deletion syndrome. The study highlights the issues regarding the overlapping clinical findings and manifestations between 1p36 deletion syndrome and PWS.

Correspondence: Kenji Kurosawa, MD, PhD, Division of Medical Genetics, Kanagawa Children's Medical Center, 2-138-4, Mutsukawa, Minami-ku, Yokohama 232-8555, Japan. Email: kkurosawa@kcmc.jp

Received 20 July 2009; revised 22 November 2009; accepted 28 December 2009.

Methods

Case reports

Patient 1

Patient 1 was the first child of healthy unrelated parents, with an unremarkable family history. The mother and father were 25 and 29 years of age, respectively, at the time of her birth. She was born at 37 weeks of gestation after an uneventful pregnancy, with a birthweight of 2360 g (–0.71 SD) and length of 46.0 cm (–0.32 SD). The patient had hypotonia and difficulty in sucking, requiring tube feeding, in the neonatal period. At age 3 her cognitive skills and motor development were moderately delayed. She crawled at 10 months, walked at 18 months, and could speak repeated words at 3 years. At age 6 the patient had hyperphagia. On physical examination at the age of 9 years, her weight was 36.9 kg (+1.16 SD), height was 129.4 cm (–0.43 SD), and occipitofrontal circumference (OFC) was 52.8 cm (+1.24 SD). The facial features included deep-set eyes associated with almond-shaped palpebral fissures, straight eyebrows, a prominent forehead, a broad and flat nasal root, and a pointed chin (Fig. 1). She